Original Article | Published:

Lymphoma

Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study

Leukemia volume 29, pages 15711577 (2015) | Download Citation

Abstract

The aim of this study was to develop a widely accepted prognostic nomogram for extranodal NK/T-cell lymphoma, nasal-type (NKTCL). The clinical data from 1383 patients with NKTCL treated at 10 participating institutions between 2000 and 2011 were reviewed. A nomogram was developed that predicted overall survival (OS) based on the Cox proportional hazards model. To contrast the utility of the nomogram against the widely used Ann Arbor staging system, the International Prognostic Index (IPI) and the Korean Prognostic Index (KPI), we used the concordance index (C-index) and a calibration curve to determine its predictive and discriminatory capacity. The 5-year OS rate was 60.3% for the entire group. The nomogram included five important variables based on a multivariate analysis of the primary cohort: stage; age; Eastern Cooperative Oncology Group performance status; lactate dehydrogenase; and primary tumor invasion. The calibration curve showed that the nomogram was able to predict 5-year OS accurately. The C-index of the nomogram for OS prediction was 0.72 for both cohorts, which was superior to the predictive power (range, 0.56–0.64) of the Ann Arbor stage, IPI and KPI in the primary and validation cohorts. The proposed nomogram provides an individualized risk estimate of OS in patients with NKTCL.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , . Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study. Br J Haematol 2012; 156: 626–632.

  2. 2.

    , , , , , et al. International Peripheral TCLP: clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931–3937.

  3. 3.

    , , , , , et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21: 1032–1040.

  4. 4.

    , , , , , et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19: 1477–1484.

  5. 5.

    , , , , , . Extranodal natural killer/T-Cell lymphoma: a population-based comparison of sinonasal and extranasal disease. Laryngoscope 2014; 124: 888–895.

  6. 6.

    , , , , , et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 2012; 138: 429–434.

  7. 7.

    , , , , , et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181–189.

  8. 8.

    , , , , , et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612–618.

  9. 9.

    , , , , , et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012; 82: 1809–1815.

  10. 10.

    , , , , , et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120: 2973–2980.

  11. 11.

    , , , , , et al. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer 2011; 117: 5203–5211.

  12. 12.

    , , , , , et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785–3790.

  13. 13.

    , , , , , et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol 2012; 29: 2183–2190.

  14. 14.

    , , , , , et al. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol 2014; 93: 1541–1549.

  15. 15.

    , , , , , et al. Clinical features and prognostic model for extranasal NK/T-cell lymphoma. Eur J Haematol 2012; 89: 103–110.

  16. 16.

    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.

  17. 17.

    , , , , , et al. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol 2012; 30: 2837–2843.

  18. 18.

    , , , , , et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: 3576–3581.

  19. 19.

    , , , , , et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol 2012; 30: 3834–3840.

  20. 20.

    , , , . Extranodal NK/T-cell lymphoma, nasal type. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thield J, Vardiman JW (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008; pp 285–288.

  21. 21.

    , , , , , . Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type NK/T-cell lymphoma of the upper aerodigestive tract. Leuk Lymphom 2014; 55: 1832–1837.

  22. 22.

    , , , , , et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008; 112: 3057–3064.

  23. 23.

    , , , , . Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182–190.

  24. 24.

    , , , , , et al. Variable clinical presentations of nasal and waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009; 15: 2905–2912.

  25. 25.

    , , , , , et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402–1408.

  26. 26.

    , , , , , et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood 2009; 114: 4771–4776.

  27. 27.

    , , , , , et al. Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. Ann Oncol 2011; 22: 390–396.

  28. 28.

    , , , , , et al. Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol 2007; 79: 1–7.

  29. 29.

    , , , , , et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216–221.

  30. 30.

    , , , , , et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998; 83: 449–456.

  31. 31.

    , , , . How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2008; 26: 1364–1370.

  32. 32.

    , , , , , et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907–913.

  33. 33.

    , , , , , et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9: 435–444.

  34. 34.

    , , , , , et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007; 18: 1382–1387.

  35. 35.

    , , , , , et al. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2007; 67: 31–38.

  36. 36.

    , , , , , et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 2012; 120: 2003–2010.

  37. 37.

    , , , , . Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia 2014; 28: 865–870.

  38. 38.

    , , , , , et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2014; 88: 806–813.

  39. 39.

    , , , , , et al. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods. J Nucl Med 2013; 54: 1039–1044.

  40. 40.

    , , , , , et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012; 82: 1115–1121.

  41. 41.

    , , , , , et al. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's Ring: dosimetric analysis and clinical outcome. Int J Radiat Oncol Biol Phys 2013; 87: 1086–1093.

  42. 42.

    , , , , , et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009; 27: 5594–5600.

Download references

Author information

Author notes

    • Y Yang
    •  & Y-J Zhang

    These authors contributed equally to this work.

Affiliations

  1. Department of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), Beijing, People’s Republic of China

    • Y Yang
    • , Q-F Liu
    •  & Y-X Li
  2. Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China

    • Y-J Zhang
  3. Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People’s Republic of China

    • Y Zhu
  4. Shanxi Cancer Hospital, Taiyuan, Shanxi, People’s Republic of China

    • J-Z Cao
  5. Cancer Hospital, Tianjin Medical University, Tianjin, People’s Republic of China

    • Z-Y Yuan
    •  & L-M Xu
  6. Fujian Provincial Cancer Hospital, Fuzhou, Fujian, People’s Republic of China

    • J-X Wu
    •  & W Wang
  7. Guizhou Cancer Hospital, Guiyang, Guizhou, People’s Republic of China

    • T Wu
    •  & B Lu
  8. Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, People’s Republic of China

    • S-Y Zhu
  9. The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China

    • L-T Qian
  10. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, People’s Republic of China

    • F-Q Zhang
    •  & X-R Hou

Authors

  1. Search for Y Yang in:

  2. Search for Y-J Zhang in:

  3. Search for Y Zhu in:

  4. Search for J-Z Cao in:

  5. Search for Z-Y Yuan in:

  6. Search for L-M Xu in:

  7. Search for J-X Wu in:

  8. Search for W Wang in:

  9. Search for T Wu in:

  10. Search for B Lu in:

  11. Search for S-Y Zhu in:

  12. Search for L-T Qian in:

  13. Search for F-Q Zhang in:

  14. Search for X-R Hou in:

  15. Search for Q-F Liu in:

  16. Search for Y-X Li in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to Y-X Li.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/leu.2015.44

Author Contributions

YXL designed the research; YXL, YY and QFL collected and analyzed the data; YJZ, YY and YXL wrote the paper; all authors provided study materials or patients and approved the paper.

Further reading